# Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

> **NCT04642079** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 839 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** 20vPnC

## Key facts

- **NCT ID:** NCT04642079
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-04
- **Primary completion:** 2022-04-06
- **Final completion:** 2022-04-06
- **Target enrollment:** 839 (ACTUAL)
- **Last updated:** 2024-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04642079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04642079, "Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04642079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*